Drug intelligence / Profile preview

GlaucoSelect

Development stage: Unknown
Lead developer: New York Eye & Ear Infirmary of Mount Sinai
Administration: Oral

Overview

GlaucoSelect is an over-the-counter nutritional supplement combination being evaluated for its neuroprotective potential in ocular diseases. Developed in association with researchers at The New York Eye & Ear Infirmary, the formulation is designed to protect retinal ganglion cells from oxidative stress, low-grade inflammation, and mitochondrial dysfunction. It is primarily studied in patients with open-angle glaucoma and diabetic retinopathy. Clinical evaluation involves the use of a Retinal Metabolic Analyzer (RMA) to measure retinal flavoprotein autofluorescence, which serves as a biomarker for mitochondrial metabolic stress and cellular dysfunction.

Brand names: GlaucoSelect
Other names: Glauco-Select

Beyond the preview

Go deeper on GlaucoSelect.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlaucoSelect.

Explore the full profile